The role of non-alcoholic fatty liver disease in the development of vascular rigidity and cardiovascular risk in patients with arterial hypertension

Purpose. To assess the parameters of lipid and carbohydrate metabolism, insulin resistance, chronic low-intensity systemic inflammation, structural and functional parameters of the liver in patients with hypertension (AH) and non-alcoholic fatty liver disease (NAFLD) compared with patients with isolated AH, as well as the impact of changes in these parameters on reducing the elasticity of the main arteries and increasing the risk of cardiovascular complications in patients with comorbid pathology.Material and methods. A comparative cross-sectional study was carried out, which included 120 patients, aged 45 to 65, with AH grade I-II, stages 1-2 (with (FLI≥60) and without NAFLD). During the initial examination, a clinical examination was carried out, the parameters of lipid, carbohydrate and structural-functional parameters of the liver were assessed. The severity of chronic systemic inflammation and insulin resistance were also assessed. Pulse wave velocity (PWV), central aortic pressure (CAP), vascular age and total cardiovascular risk were measured according to the SCORE scale.Results. The data obtained indicate a more pronounced insulin resistance, chronic systemic inflammation, as well as significantly higher lipid metabolism in patients with AH and NAFLD in comparison with patients with isolated AH. In addition, in patients of this group, the indicators of PWV and CAP were significantly higher, and patients with AH and NAFLD had a higher 10-year fatal risk (p=0.013). The performed ROC analysis showed that at FLI≥60, a high risk of PWVm>10m/s is predicted. Multiple regression analysis found that an increase in VLDL cholesterol leads to an increase in the values of both PWVe (p<0.001) and PWVb (p=0.048). The 10-year fatal risk (SCORE) in patients with AH and NAFLD increased with an increase in PWVe (p=0.021), FLI (p=0.013), and visceral obesity (p<0.001).Conclusion. The study shows that in patients with AH and NAFLD, compared with patients with isolated AH, the indicators of insulin resistance and chronic low-intensity systemic inflammation are significantly higher, the highly atherogenic type of hyperlipidemia and visceral obesity are more often found. Also, in comorbid patients with AH, statistically significant higher values of CAP and augmentation index are determined. Stiffness indices of the great arteries were also significantly higher in patients with comorbid pathology. The ROC analysis showed that at FLI≥60, a high risk of PWVm>10 m/s was predicted, which is associated with the development of cardiovascular complications. Also, multiple regression analysis showed that the increase in PWVe and PWVm was mainly due to an increase in VLDL cholesterol, and the 10-year fatal cardiovascular risk of complications had the greatest increase with an increase in the values of PWVe, FLI and visceral obesity.

Short-Term Intake of Yellowstripe Scad versus Salmon Did Not Induce Similar Effects on Lipid Profile and Inflammatory Markers among Healthy Overweight Adults despite Their Comparable EPA+DHA Content

Yellowstripe scad (YSS) have comparable eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA) content to salmon. We aimed to compare the effects of YSS and salmon on lipid profile and inflammatory markers. A randomized crossover trial with two diet periods was conducted among healthy overweight (with BMI 23.0–27.4 kg/m2) Malaysian adults aged 21–55 years. Steamed whole YSS fish (≈385 g whole fish/day) or salmon fillets (≈246 g fillet/day) were given for eight weeks (3 days per week), retaining approximately 1000 mg EPA+DHA per day. Diets were switched after an 8-week washout period. Fasting blood samples were collected before and after each diet period. A total of 49 subjects participated in the intervention (35% male and 65% female; mean age 29 (7) years). YSS did not induce any significant changes in outcome measures. However, the consumption of salmon as compared with YSS was associated with reduction in triglycerides (between-group difference: −0.09 mmol/1, p = 0.01), VLDL-cholesterol (between-group difference: −0.04 mmol/1, p = 0.01), atherogenic index of plasma (between-group difference: −0.05 mmol/1, p = 0.006), and IL-6 (between-group difference: −0.01 pg/mL, p = 0.03). Despite their comparable EPA+DHA content, short-term consumption of salmon but not YSS induced significant changes in lipid profile and inflammatory markers. Larger clinical trials are needed to confirm the findings.

TÁC DỤNG ĐIỀU CHỈNH RỐI LOẠN LIPID MÁU CỦA VIÊN NANG LINH QUẾ TRUẬT CAM – NHỊ TRẦN THANG GIA VỊ TRÊN CHUỘT CỐNG TRẮNG

Mục tiêu: Đánh giá tác dụng điều chỉnh rối loạn lipid máu của viên nang Linh quế truật cam thang - Nhị trần thang gia giảm (LQTCT-NTT) trên chuột cống trắng rối loạn lipid máu ngoại sinh. Phương pháp: Chuột cống trắng được gây rối loạn lipid máu bằng cách cho uống hỗn hợp dầu cholesterol, sau đó 2 giờ được cho uống thuốc nghiên cứu, liên tục trong 28 ngày. Đánh giá các chỉ số lipid máu, hình ảnh đại thể, vi thể gan chuột. Kết quả: LQTCT-NTT liều 0,28g/kg/ngày và 0,56g/kg/ngày làm giảm các chỉ số lipid máu gồm Triglyceride, cholesterol TP, LDL- Cholesterol, VLDL- Cholesterol; giảm chỉ số Atherogenic; tăng HDL-Cholesterol máu; giảm mỡ bụng, giảm tình trạng nhiễm mỡ gan. Các tác dụng này của LQTCT-NTT tương đương với Atorvastatin liều 10mg/kg/ngày. Kết luận: Viên nang LQTCT-NTT có tác dụng tốt trong điều chỉnh rối loạn lipid máu ngoại sinh trên chuột cống trắng.

Hypocholesterolemic Effect of Blackcurrant (Ribes nigrum) Extract in Healthy Female Subjects: A Pilot Study

Blackcurrant extract (BCE) ameliorates dyslipidemia in menopausal model animals and in elderly women at a risk of dyslipidemia. However, it is unknown whether the daily intake of BCE can prevent lipid abnormalities in healthy individuals. Lipids are essential for the body, but they also cause arteriosclerosis. In this noncomparative pilot study, we examined the effects of BCE administered for 29 days on serum lipids in young healthy women. Blood samples were collected before and on days 4 and 29 after BCE intake, and 20 lipoprotein fractions in the serum were separated using a gel-permeation high-performance liquid chromatography method to measure the triacylglycerol and cholesterol levels in lipoproteins. There were no effects on lipids on day 4 of BCE intake, but the total cholesterol level decreased on day 29. Furthermore, the levels of total very-low-density lipoprotein (VLDL) cholesterol, small VLDL cholesterol, and large low-density lipoprotein cholesterol were significantly decreased. These results suggest that the daily intake of BCE has a hypocholesterolemic effect in healthy women, and that it is effective in preventing atherosclerosis.

Ascorbic supplementation attenuates juglone induced metabolic derangement

Juglone derivatives like 2-(4-hydroxyphenyl) amino-1,4-naphthoquinone (Q7) are used as antitumor agents, and act through reactive oxygen species (ROS) generation. Such may lead to abnormal lipid metabolism and ROS dysregulation. The objective of this study was to evaluate the effect of ascorbate on the metabolism of lipids and carbohydrates following Q7-induced oxidative stress. Male Wistar rats were administered Q7 (10 mg/Kg) and/or ascorbate (500 mg/Kg) orally for 20 days. Rats treated with Q7 showed an increase in serum triglycerides, VLDL cholesterol and lipid peroxidation levels. When Q7 treatment was followed up by ascorbate (500 mg/Kg) administration, we observed a reduction in serum triglycerides, VLDL cholesterol and lipid peroxidation. The oral administration of ascorbate reduced the Q7-induced increases in lipids, and postprandial glycemia. This could be associated with the redox activity of ascorbate that reduced the oxidative stress induced by Q7. We thus conclude that ascorbate modulates the Q7-induced increase of lipid and carbohydrate metabolism.

Effect of antiepileptic drugs on various lipid fractions and certain liver enzymes in epileptic patients of Punjab origin

Introduction and Aim: Epilepsy requires lifelong therapy with antiepileptic drugs (AEDs) &having medical and psychological consequence. Present study was conducted to observe the effect of different AEDs on lipid profile and certain liver enzymes on epileptic patients. Material and Methods: 50 epileptic patients receiving AEDs for minimum 1 year were recruited as study group and 50 healthy subjects considered as control group. These subjects were recruited from general community of Punjab. Fasting blood samples were drawn from patients and healthy subjects for the evaluation of total cholesterol, triglycerides, LDL-cholesterol, VLDL-cholesterol, HDL-cholesterol, AST, ALT & ALP. Results: Significant increase in total cholesterol, triglycerides, LDL-cholesterol, VLDL- cholesterol was observed in epileptic patients while no significant change was recorded in HDL- cholesterol. Maximum increase in total cholesterol, TGs, LDL-cholesterol, VLDL- cholesterol levels was observed in phenytoin treated patients with reference tovalproic acid, carbamazepine, levetiracetam treated patients. Levels of AST, ALT and ALP were significantly increased in epileptic patients. Maximum increase in AST & ALT was observed in levetiracetam treated epileptic patients and maximum rise in ALP levels was found in carbamazepine treated patients with reference to other AEDs treated patients. Conclusion: Aforementioned observations suggested that epileptic patients treated with phenytoin, valproic acid, carbamazepine & levetiracetam for long time could cause dyslipidemia, might be responsible for various CHD’s and hepatotoxicity in epileptic patients. Routine screening of lipid profile and hepatic enzymes during chronic use of AEDs is recommended.